Evidence map›Paper›PMID 37398154›Full record

ArticleResearch square2023

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia.

Ian M Bouligny, Graeme Murray, Thuy Ho, Michael Doyel, Tilak Patel, Josh Boron, Valerie Tran, Juhi Gor, Yiwei Hang, Yanal Alnimer and 5 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in Research square, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Ian M BoulignyVirginia Commonwealth University Massey Cancer Center - NCI Designated Comprehensive Cancer Center, Division of Hematology and Oncology, Department of Internal Medicine, 1001 E. Leigh St., Richmond, VA, USA.ORCID 0000-0002-4274-4249
Graeme MurrayVirginia Commonwealth University School of Medicine, 1201 E. Marshall St., Richmond, VA, USA.
Thuy HoVirginia Commonwealth University Massey Cancer Center - NCI Designated Comprehensive Cancer Center, Division of Hematology and Oncology, Department of Internal Medicine, 1001 E. Leigh St., Richmond, VA, USA.
Michael DoyelVirginia Commonwealth University School of Medicine, 1201 E. Marshall St., Richmond, VA, USA.
Tilak PatelVirginia Commonwealth University Medical Center, Department of Internal Medicine, 1101 E. Marshall St., Richmond, VA, USA.
Josh BoronVirginia Commonwealth University Medical Center, Department of Internal Medicine, 1101 E. Marshall St., Richmond, VA, USA.
Valerie TranVirginia Commonwealth University Medical Center, Department of Internal Medicine, 1101 E. Marshall St., Richmond, VA, USA.
Juhi GorVirginia Commonwealth University Medical Center, Department of Internal Medicine, 1101 E. Marshall St., Richmond, VA, USA.
Yiwei HangVirginia Commonwealth University School of Medicine, 1201 E. Marshall St., Richmond, VA, USA.
Yanal AlnimerVirginia Commonwealth University Medical Center, Department of Internal Medicine, 1101 E. Marshall St., Richmond, VA, USA.
Kyle ZacholskiVirginia Commonwealth University Medical Center, Department of Pharmacy, 410 North 12 St., Richmond, VA, USA.
Chad VennVirginia Commonwealth University Medical Center, Department of Pharmacy, 410 North 12 St., Richmond, VA, USA.
Nolan A WagesVirginia Commonwealth University School of Medicine, Department of Biostatistics, 830 E. Main St., Richmond, VA, USA.
Steven GrantVirginia Commonwealth University Massey Cancer Center - NCI Designated Comprehensive Cancer Center, Division of Hematology and Oncology, Department of Internal Medicine, 1001 E. Leigh St., Richmond, VA, USA.
Keri R MaherVirginia Commonwealth University Massey Cancer Center - NCI Designated Comprehensive Cancer Center, Division of Hematology and Oncology, Department of Internal Medicine, 1001 E. Leigh St., Richmond, VA, USA.
Virginia Commonwealth University · US

Funding

Virus Vector Shared ResourceP30CA016059 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI Kim Felder Rhoads · 1985 to 2026
$51.0M
Research Supplement to Promote Diversity in Health Related ResearchUL1TR002649 · NCATS · VIRGINIA COMMONWEALTH UNIVERSITY · PI MOELLER, FREDERICK GERARD · 2018 to 2022
$19.1M
NCATS NIH HHS UL1 TR002649NCI NIH HHS P30 CA016059
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AMLhypomethylating agentrefractoryrelapsedvenetoclax

Identifiers

PMID37398154
PMCPMC10312962
OpenAlexW4380303010

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.